ZSQR Overview

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its segments are Biotechnology and Technology. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Wall Street analysts forecast ZSQR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZSQR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Coeptis Therapeutics Holdings Inc revenue for the last quarter amounts to 862.05K USD, decreased

Coeptis Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.29 USD, decreased -69.47

Coeptis Therapeutics Holdings Inc (ZSQR) has 4 emplpoyees as of May 08 2026.

Today ZSQR has the market capitalization of 668.47M USD.